Raw Ground Truth
Inclusion Criteria:Participant has cancerParticipant is treated with an oral or injectable Food and Drug Administration (FDA)-approved EGFRi or MEKi therapyParticipant has EGFRi/MEKi-related acneiform rash of Grade ≥ 2 as per common terminology criteria for adverse events (CTCAE) version 5.0, and ≥ 20 inflammatory lesions on the face at screening and Day 1.Exclusion Criteria:Participant has infected EGFRi/MEKi-associated acneiform rash according to investigator's evaluation.Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Raw Prediction
Inclusion Criteria:
Subject has cancer
Subject is treated with an oral or injectable FDA-approved EGFRi or MEKi therapy
Subject has EGFRi/MEKi-related acneiform rash of Grade ≥ 2 as per CTCAE Version 5.0, and ≥ 20 inflammatory lesions on the face at screening and Day 1.
Subject is screened for inclusion.
Exclusion Criteria:
Subject has infected EGFRi/MEKi-associated acneiform rash according to Investigator's evaluation.
Subject is unable to comply with study procedures due to COVID-19 related center closures.
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Processed Ground Truth
1. Participant has cancerParticipant is treated with an oral or injectable Food and Drug Administration (FDA)-approved EGFRi or MEKi therapyParticipant has EGFRi/MEKi-related acneiform rash of Grade ≥ 2 as per common terminology criteria for adverse events (CTCAE) version 5.0, and ≥ 20 inflammatory lesions on the face at screening and Day 1.Exclusion Criteria:Participant has infected EGFRi/MEKi-associated acneiform rash according to investigator's evaluation.Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Processed Prediction
1. Subject has cancer
2. Subject is treated with an oral or injectable FDA-approved EGFRi or MEKi therapy
3. Subject has EGFRi/MEKi-related acneiform rash of Grade ≥ 2 as per CTCAE Version 5.0, and ≥ 20 inflammatory lesions on the face at screening and Day 1.
4. Subject is screened for inclusion.
1. Subject has infected EGFRi/MEKi-associated acneiform rash according to Investigator's evaluation.
2. Subject is unable to comply with study procedures due to COVID-19 related center closures.
3. Note: Other protocol defined Inclusion/Exclusion criteria may apply.